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Abstract
Background: Fibroblasts play important roles in several cancers. It was hypothesized that cholangiocarcinoma
(CCA)-associated fibroblasts (Cfs) differ from non-tumorigenic liver fibroblasts (Lfs) in their gene expression profiles
resulting in the capability to promote cancer. Periostin (PN) is a multi-functional protein and has emerged as a
promising marker for tumor progression. The role of PN in CCA, however, has not yet been explored.
Results: In this study, the gene expression profile of Cfs in comparison to Lfs was performed using oligonucleotide
microarrays. The common- and unique-expressed genes in Cfs and the promising roles in cancer promotion and
progression were determined. PN was markedly over-expressed in Cfs confirmed by real time RT-PCR and western
blot analysis. Immunohistochemistry examination of a number of patients with intrahepatic CCA showed the
expression of PN solely in stromal fibroblasts, but was expressed neither in cancer cells nor immune cells. Low to
no expression of PN was observed in tissues of benign liver disease and hepatocellular carcinoma. CCA patients
with high levels of PN had significantly shorter survival time than those with low levels (P = 0.026). Multivariate
analysis revealed high levels of PN (P = 0.045) and presence of lymph node metastasis (P = 0.002) as independent
poor prognostic factors. The in vitro study revealed that recombinant PN induced CCA cell proliferation and
invasion. Interestingly, interference RNA against integrin a5 significantly reduced the cellular response to
PN-stimulated proliferation and invasion.
Conclusion: The gene expression profile of fibroblasts in CCA is apparently explored for the first time and has
determined the genes involving in induction of this cancer progression. High PN can be used to distinguish CCA
from other related liver diseases and is proposed as a prognostic factor of poor survival. Regulation of fibroblast-
derived PN in CCA proliferation and invasion may be considered as an alternative therapeutic approach.
Background
Cholangiocarcinoma (CCA) originates from biliary
epithelial cells and is a unique cancer in northeastern
Thailand where the prevalence of a liver fluke,
Opisthorchis viverrini infection is higher than elsewhere
in the country. A recent study showed a strong positive
correlation of CCA incidence and the prevalence of O.
viverrini infection [1]. In other countries, CCA has been
shown to correlate with Clonorchis sinesis [2,3], and
chronic biliary diseases [4]. Even though CCA is caused
from the different etiologies, it is well recognized to
contain an abundant fibrous stroma that is mainly com-
posed of a-smooth muscle actin (SMA) positive fibro-
blasts [5,6]. In addition, the degree of a-SMA expression
has been shown to correlate with the survival of
patients, in part, via the ability of these cancer-asso-
ciated fibroblasts to induce proliferation of bile duct
epithelial and cancer cells [6].
The ability of stromal fibroblasts to generate a favor-
able microenvironment for cancer cells leading to cancer
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ized [7,8]. Mitotic substances have been produced from
stromal fibroblasts to promote tumor growth in many
cancers [9,10]. In addition, some matrix metalloprotei-
nases which are often mentioned as proteolytic sub-
stances of the extracellular matrix (ECM) and have been
reported to show increased production from cancer stro-
mal fibroblasts. These proteolytic substances appear to
help to promote cancer cell invasion and metastasis [11].
Specifically, in CCA, stromal-derived factor 1 (SDF-1)
has been secreted from stromal fibroblasts into the
microenvironment in which it was located at the edge of
cancer masses and was proposed to play important role
in induction of CCA cell invasion and metastasis [12].
To understand the roles of fibroblasts in carcinogen-
esis, cancer promotion and progression, gene profiling
of cancer fibroblasts have been studied in many cancers
[13-15]. Stromal cancer fibroblasts from breast cancer
with invasion were compared with the expression pro-
files of fibroblasts in benign breast disorders. HYL
(Csk-homologous kinase CHK) involving in regulation
of Src kinase, GM CSF-1 (granulocyte monocyte colony
stimulating factor-1) and osteopontin were up-regulated
which may result in induction of tumor growth and
metastasis [13]. Among genes encoded for secreted pro-
teins over-expressed in fibroblasts of human basal cell
carcinoma [14], genes including CTSK (cathepsin K),
SFRP2 (secreted frizzled-related protein 2), PDGFRL
(platelet-derived growth factor receptor-like protein),
and DCN (decorin) were shown to be up-regulated in
non-epithelial cells of breast cancer [16]. In contrast,
these genes could not be detected in fibroblasts isolated
from cancers of pancreas [17], and liver metastases of
colon cancer [18]. Taken together, it is possible to say
that differential gene expression profile of cancer fibro-
blasts is partly similar but actually unique for each can-
cer type. This supports the importance of specific
recognition of the concerted performance between fibro-
blasts and epithelial cells in carcinogenesis and progres-
sion in different organs of origin. So it is of great value
to investigate the specific gene expression profile of the
CCA-derived fibroblasts to help us better understand
the molecular mechanisms that fibroblasts use to pro-
mote cancer.
Periostin (PN) is a secreted protein which was first
identified in bone and implicated in regulating adhesion
and differentiation of osteoblasts. The cancer biology
role of PN has been investigated in a wide range of can-
cers including cell proliferation [19,20], migration [21],
invasion/metastasis [22,23], and angiogenesis [23,24].
When not regarding the specific sources, either from
cancer cells or fibroblasts, secreted PN has been
reported to induce tumorigenic properties of epithelial
cells via the activation of integrins (ITGs) receptors [21].
Even though substantial evidence has shown that can-
cer-associated fibroblasts are involved in tumor promo-
tion and with the evidence that fibroblasts in CCA
induce more aggressive tumorigenic properties of cancer
cells [6], the role of CCA-derived fibroblasts in this can-
cer is yet to be determined. In the present study, fibro-
blasts isolated from CCA tissues or CCA-associated
fibroblasts (Cfs) which were already characterized by the
present group [6], were explored. The genome wide
expressions of these Cfs were determined and compared
to non-tumorigenic liver fibroblasts (Lfs). The altered
expression of genes focusing on the impact of soluble
products from Cfs on the promotion and progression of
CCA was investigated. Interestingly, PN, which has
never been reported in CCA was found at a high level
whereas no-to-low PN was detected in non-tumor liver
tissues and cancer of hepatocytes. The overexpression of
PN in CCA tissues was detected solely in fibroblasts and
associated with poor prognosis and short survival of the
patients. The effect of PN to induce cell proliferation
and invasion has been examined.
Results
Gene expression analysis of Cf and validation by real
time RT-PCR
To reduce the genetic background of different patients,
the gene expression profile of Cfs was compared to those
of two Lfs namely Lf1 and Lf2. Lf1 was isolated from
non-tumorigenic liver tissues of hepatectomized liver
from the CCA patient who Cfs were originated from.
The Lf2 was isolated from the other CCA patient. Genes
with differential expressed levels in Cf compared to Lf1
were 3,560 for 2-fold or more up-regulation and 2,339
for 0.5-fold or less down regulation (Fig 1A and 1B). The
comparison of the Cf to Lf2 was 4,579 and 3,348 for up-
and down-regulation. The common differential genes
which are genes altered in their expressions in Cfs when
compared to both Lf1 and Lf2 (Cf/Lfs), were 1,466 for
up-regulation and 495 for down-regulation. Arylaceta-
mide deacetylase (DAC), procollagen C endopeptidase
enhancer 2 (PCPE2), serpin peptidase inhibitor (PAI) and
S100 calcium binding protein A4 (S100A4)w e r ep r e d o -
minantly over-expressed at high levels in Cfs whereas
bone morphogenic protein 2 (BMP2), matrix-remodeling
associated 5 (DKFZp564I1922), bradykinin receptor B1
(BRADYB1), response gene to complement 32 (RGC32)
and interleukin 24 (IL-24) were down-regulated with a
high array intensity (Table 1).
Most of common differentially expressed genes in Cfs
play roles in controlling cellular metabolism (Table 2 and
Table 3). The up-regulated genes encoded for secreted
proteins were mostly classified in groups of extracellular
region, proteolysis, and ECM organization/biosynthesis
which took up to 11% of total genes (Table 2). Among
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genes that act in cell proliferation and motility, 11 genes
having several tumorigenic functions were selected for
further exploration including a disintegrin and matrix
metalloproteinase 12 (ADAM12), amphiregulin (AREG),
angiopoietin (AGN2), epiregulin (ER), jagged1 (JAGL1),
laminin alpha 5 (LAMA5), nephroblastoma over
expressed (NOV), platelet-derived growth factor-a
(PDGF-A), periostin (PN), reelin (RL), and secretogranin
2( SCG2) (Fig 1A).
The up-regulated levels of these genes in Cfs were
verified by relative quantification using real time
RT-PCR. In concordance with microarray data, real time
RT-PCR results revealed that ADAM12, AREG, ER,
JAGL1, PDGF-A, PN and SCG2 had significant up-regu-
lations in Cfs compared to Lfs, but that of NOV was not
statistically significantly increased (Fig 1C). ANG2,
LAMA5,a n dRL, however, showed the opposite direc-
tion to the microarray results.
Detection of PN expression in Cf and CCA tissues
Using different biological preparation lots of Cfs from
those used in microarray analysis, both real time RT-
PCR and western blot analysis confirmed that Cfs had
higher expressions of PN than Lfs with statistical signifi-
cance (Fig 2A and 2B). The expression of PN in KKU-
100, KKU-M055, KKU-M156 and KKU-M213 CCA cell
lines was detected at a very low level compared to the
high expression in Cfs (Fig 2C).
To check whether the increased expression of PN
mRNA can be found in CCA tissues, real time PCR was
performed using total RNA extracted from pieces of
CCA mass. Using b-actin and gapdh as the internal con-
trols, the results showed the median of PN mRNA
expression was higher in CCA tissues (4.347 and 2.449
using b-actin and gapdh respectively) than in benign
liver tissues (1.064 and 1.625, respectively) (Fig 2D).
This increased up-regulation was not statistically signifi-
cant. In addition, to achieve the aim to use a rapid
method such as real time PCR in place of immunohisto-
chemical detection of PN in CCA tissues, the PN
mRNA level was related to the intensity of PN immu-
noreactivity detected by immunohistochemistry. The
results indicated the positive correlation of PN mRNA
level and the encoding protein found in CCA tissues
with statistical significance (P = 0.045) (Fig 2E).
Expression of PN in CCA tissues and clinicopathological
relevance
Immunohistochemistry revealed that the expression of
PN was exclusively localized in fibroblasts but not cancer
cells (Fig 3). Of all 52 cases, 43 cases or 83% were PN
Figure 1 Genome wide expression analysis of Cf and Lfs and gene validation by real time PCR. A Vane diagram showed common up-
regulated genes (A) and common down-regulated genes (B) in Cf (Cf/Lfs). In this study, eleven genes encoded secreted proteins involved in
induction of epithelial cell tumorigenesis including proliferation, invasion, metastasis and angiogenesis were selected from 4 main different
groups of biological functions (A). The numbers in the parentheses represent folds of gene expression level of Cf over those in Lfs. The results
show the comparison of gene expression levels measured by real time PCR and oligonucleotide microarray (C). Folds of expression represent
fold changes of gene expression level in Cfs as compared to that in Lfs.
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them showed high expression levels. High expression of
PN was observed in well- (Fig 3A), moderately- (Fig 3B)
and poorly-differentiated malignant tissues (Fig 3C). For
PN-negative CCA tissues, only 17% (9/52) were in this
group in which no PN was detected in either fibroblasts
or cancer cells (Fig 3D). In contrast, benign liver tissues
showed no (2/8) to slight (6/8) PN expression. Similar to
benign liver tissues, hepatocellular carcinoma revealed
low PN expression in their stromal cells (Fig 3E and 3F).
Moreover, double immunofluorescence staining revealed
co-localization of a-SMA and PN in the fibroblasts
within cancerous area (Fig 3G).
Cumulative survival of CCA patients with low or high
PN expression in cancer stromal fibroblasts was ana-
lyzed using the Kaplan-Meier method. The patients with
Table 1 List of top 20 common up-regulated genes and top 20 common down-regulated genes.
Gene Abbreviation Intensity Mismatch Ratio
Common up-regulated genes of Cf binding Cf/Lfs
arylacetamide deacetylase (esterase) DAC 115.92 P 956.45
sparc/osteonectin (testican 3) SPOCK3 16.70 P 669.24
neuropeptide Y receptor Y1 NPYR 20.86 P 416.71
collagen, type XIV, alpha 1 (undulin) COL14A1 47.74 P 245.03
growth associated protein 43 B-50 23.52 P 232.10
procollagen C-endopeptidase enhancer 2 PCPE2 117.81 P 224.83
sorbin and SH3 domain containing 2 SORB2 10.65 P 192.25
myozenin 2 MYOZ2 6.53 P 139.50
serpin peptidase inhibitor, clade B (ovalbumin), member 2 transcript variant 2 PAI2 260.13 P 133.32
doublecortin-like kinase 1 DCLK 19.11 P 112.57
formyl peptide receptor-like 2 FPRL2 3.24 P 111.02
contactin associated protein-like 3 CASPR3 5.09 P 106.75
integrin, beta-like 1 (with EGF-like repeat domains) ITGBL1 13.35 P 82.92
collagen, type IV, alpha 6 COL4A6 76.71 P 77.06
myc target 1 MYCT1 28.15 P 73.88
S100 calcium binding protein A4 S100A4 103.88 P 72.30
phosphodiesterase 1A, calmodulin-dependent HSPDEA1 12.50 P 71.51
neurofilament, light polypeptide 68 kDa NEFL 5.71 P 69.33
ADAMTS-like 1 ADAMTSR1 3.24 P 68.55
early B-cell factor 1 EBF 4.57 P 60.80
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 5
SIAT7E 0.02 P 3943.41
fibrillin 2 (congenital contractural arachnodactyly) FBN2 0.05 P 1035.17
fibroblast growth factor receptor 2 FGFR2 0.04 P 684.03
pregnancy specific beta-1-glycoprotein 5 PSG 0.07 P 349.77
Sal-like 1 (Drosophila) SALL1 0.03 P 312.29
membrane metallo-endopeptidase MME 0.05 P 274.25
odz, odd Oz/ten-m homolog 2 (Drosophila) TEN-M2 0.93 P 134.10
R-spondin 3 homolog (Xenopus laevis) RSPO3 0.4 P 70.16
bone morphogenetic protein 2 BMP2A 1.19 P 68.96
neuroligin 4, Y-linked NLGN4Y 0.09 P 68.62
matrix-remodelling associated 5 DKFZp564I1922 1.31 P 57.89
collagen, type IV, alpha 4 COL4A4 0.67 P 49.71
bradykinin receptor B1 BRADYB1 1.61 P 48.96
microfibrillar-associated protein 4 MFAP4 0.3 P 32.40
matrix metallopeptidase 3 (stromelysin 1, progelatinase) MMP-3 0.85 P 30.01
chromosome 13 open reading frame 15 RGC32 1.69 P 28.40
fibroblast growth factor 13 FGF13 0.38 P 28.15
ephrin receptor A5 EPHA5 0.40 P 25.68
interleukin 24 IL-24 1.68 P 25.27
Only those having transcripts, not EST or clones in cDNA library are listed.
P = presence to detectable intensity
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Gene ontology (%) Accession
no.
Description Ratio
Cellular metabolism (23.7%) NM_000909 neuropeptide Y receptor Y1 416.71
NM_004734 doublecortin-like kinase 1 112.57
NM_002961 S100 calcium binding protein A4 72.30
AF208502 early B-cell factor 1 60.80
AW004016 ST6 beta-galactosamide alpha-2,6 sialyltransferase 2 59.04
Protein binding (20.8%) BF449063 collagen, type XIV, alpha 1 (undulin) 245.03
NM_002045 growth associated protein 43 232.10
AI659533 sorbin and SH3 domain containing 2 192.25
BF939176 myozenin 2 139.5
AF333769 contactin associated protein-like 3 106.75
Signal transduction (10.9%) AW026543 formyl peptide receptor-like 2 111.02
NM_004791 integrin, beta-like 1 82.92
NM_005019 phosphodiesterase 1A 71.51
AF159570 regulator of G-protein signalling 5 49.64
W67461 angiopoietin-like 1 49.16
Extracellular region (7.8%) NM_001086 arylacetamide deacetylase (esterase) 956.45
AI808090 Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3 669.24
NM_013363 procollagen C-endopeptidase enhancer 2 224.83
AI889941 collagen, type IV, alpha 6 77.06
NM_052866 a disintegrin and metalloproteinase with thrombospondin motif-like 1 68.55
Transcription factor (7.5%) AF332197 sine oculis homeobox homolog 2 44.20
AI681917 iroquois homeobox protein 3 35.34
NM_020639 receptor-interacting serine-threonine kinase 4 29.41
AK023792 PBX/knotted 1 homeobox 2 29.40
AF208967 paternally expressed 3 26.74
Protein modification (5.5%) AW975934 Titin 32.01
NM_020639 receptor-interacting serine-threonine kinase 4 29.41
NM_000222 v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 25.21
BF446673 hemicentin 1 18.96
NM_002848 protein tyrosine phosphatase, receptor type, O 14.58
Receptor (4.8%) BF941499 G protein-coupled receptor 116 35.62
L35594 ectonucleotide pyrophosphatase/phosphodiesterase 2 32.11
NM_002820 parathyroid hormone-like hormone 30.44
U61276 jagged 1 (Alagille syndrome) 19.60
AK022548 integrin, alpha 7 15.62
Cell differentiation (4.3%) AA343027 Sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
(semaphorin) 3D
67.06
NM_000216 Kallmann syndrome 1 sequence 27.91
AL560266 Fc receptor-like A 19.61
AA127691 neuropilin 2 19.35
NM_002506 nerve growth factor, beta polypeptide 19.11
Cell adhesion (3.5%) NM_006727 cadherin 10, type 2 (T2-cadherin) 55.43
NM_000072 CD36 molecule (thrombospondin receptor) 40.71
AL573851 endothelial cell adhesion molecule 22.52
N69091 protocadherin 17 22.32
AA489646 protocadherin beta 13 19.36
Cell cycle (2.4%) NM_003914 cyclin A1 34.8
NM_015714 G0/G1switch 2 26.62
NM_001759 cyclin D2 16.45
NM_001992 coagulation factor II (thrombin) receptor 13.90
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tive deaths (n = 1) and excluded from the analysis. Med-
ian survival time was 395 ± 157 d for patients with low
and 179 ± 35 d for patients with high PN expression.
We found that the patients with high PN positive fibro-
blasts had statistically significantly shorter survival times
than those with low PN positive fibroblasts (P =0 . 0 2 6 )
(Fig 4). The prognostic value of PN expression and
other clinicopathological factors among CCA patients
was analyzed using multivariate Cox Proportional
Hazard Regression model. The results revealed that high
PN expression (HR = 2.02, P = 0.045), and the presence
of lymph node metastasis (HR = 3.13, P =0 . 0 0 2 )w e r e
the independent risk factors for the overall survival of
CCA patients after hepatectomy (Table 5). However,
lymph node metastasis and other clinical data showed
no association with PN expression (Table 6).
PN promotes proliferation and invasion of CCA cells
PN could induce proliferation of KKU-M156, KKU-M213
and KKU-M055 CCA cell lines (Fig 5A-C), but not KKU-
100 (Fig 5D). In addition, KKU-M156, KKU-M213 and
KKU-M055 responded to the proliferative effect of
optimal PN concentration in a time dependent manner
with statistical significance at the 24 h-treatment for all
cell types (Fig 5E). To reinforce the proliferation effect of
PN on CCA cell lines, colony formation assay with and
without soft agar were performed and the result indicated
the increased numbers of colonies in the condition of PN
treatment in comparison to the negative control without
PN stimulation (Fig 5F). In addition, flow cytometric ana-
lysis indicated an increased number of KKU-M213 and
KKU-M156 cells distributed in S+G2/M when exposed
to PN (Fig 6A and 6B).
To address the invasion effect of PN on CCA cells, the
invasion assay of cell lines with high ITGa5 expression
was performed in a Boyden chamber. The results
showed that exogenous PN could markedly induce inva-
sion of KKU-M156 and KKU-M213 CCA cell lines up
to around 210% and 230% of cells without PN treatment
(Fig 6C).
Knockdown of ITGa5 attenuates PN-induced proliferation
and invasion
Treatment of CCA cells with siITGa5 and lipofectamine
(mock) for 6 h did not affect cell viability (Fig 7A). The
Table 2: Gene ontology of common up-regulated genes. Only genes in the top-five ranking of each group are shown. (Continued)
AK024082 Tousled-like kinase 2 11.09
Cell motility (2.2%) NM_005045 reelin 17.30
NM_003062 slit homolog 3 (Drosophila) 5.12
M21121 chemokine (C-C motif) ligand 5 5.06
NM_014795 zinc finger E-box binding homeobox 2 4.85
D45864 protein kinase, cGMP-dependent, type I 4.74
Proteolysis (2.0%) NM_001870 carboxypeptidase A3 (mast cell) 20.01
NM_024539 ring finger protein 128 12.68
AL574912 protease, serine, 35 11.59
NM_001873 carboxypeptidase E 9.45
NM_000892 kallikrein B, plasma (Fletcher factor) 1 6.40
Cell proliferation (2.0%) U77914 jagged 1 (Alagille syndrome) 16.76
NM_004624 vasoactive intestinal peptide receptor 1 13.07
BF514079 Kruppel-like factor 4 (gut) 12.89
NM_001432 epiregulin 11.98
BC003355 laminin, alpha 5 10.36
Apoptosis (1.6%) NM_002575 serpin peptidase inhibitor 133.32
NM_000557 growth differentiation factor 5 14.79
NM_003728 unc-5 homolog C (C. elegans) 9.60
BF432648 tumor necrosis factor receptor superfamily 8.73
NM_003551 non-metastatic cells 5, protein expressed in (nucleoside-diphosphate kinase) 6.80
ECM organization and biosynthesis
(0.9%)
BC001186 protocadherin beta 5 15.90
M25813 tenascin XB 12.46
NM_002380 matrilin 2 4.89
AY140646 periostin, osteoblast specific factor 2 4.89
NM_004612 transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53
kDa
4.56
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Gene ontology (%) Accession
no.
Description Ratio
Cellular metabolism
(31.6%)
NM_030965 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 5
3943.41
NM_022969 fibroblast growth factor receptor 2 684.03
AU152837 Sal-like 1 (Drosophila) 312.29
NM_007287 membrane metallo-endopeptidase 73.38
BF589322 R-spondin 3 homolog (Xenopus laevis) 70.16
Signal transduction
(17.8%)
NM_001200 bone morphogenetic protein 2 68.96
NM_000710 bradykinin receptor B1 48.96
R72286 microfibrillar-associated protein 4 32.40
NM_004114 fibroblast growth factor 13 28.15
BE218107 EPH receptor A5 25.68
Transcription factor
(11.5%)
AJ277914 LIM homeobox 9 25.01
NM_001452 forkhead box F2 18.08
AA705845 transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) 17.16
BG261252 ecotropic viral integration site 1 11.58
NM_020327 activin A receptor, type IB 9.32
Protein modification
(7.9%)
AF245505 matrix-remodelling associated 5 57.89
AA725644 ubiquitin specific peptidase 42 18.73
NM_001982 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 11.34
AV727260 protein tyrosine phosphatase, receptor type, D 10.93
NM_002570 proprotein convertase subtilisin/kexin type 6 9.83
Cell differentiation (6.2%) NM_000641 interleukin 11 17.51
BC006454 growth arrest-specific 7 15.20
M69148 midkine (neurite growth-promoting factor 2) 14.03
NM_003991 endothelin receptor type B 10.85
AI758962 EPH receptor A4 7.15
Cell adhesion (5.9%) NM_001999 fibrillin 2 1035.17
NM_014893 neuroligin 4, Y-linked 68.62
AI694562 collagen, type IV, alpha 3 22.21
NM_005864 embryonal Fyn-associated substrate 8.44
AU146651 collagen, type XII, alpha 1 4.89
Cell cycle (5.9%) NM_014059 chromosome 13 open reading frame 15 28.40
M19701 retinoblastoma 1 (including osteosarcoma) 4.93
NM_002009 fibroblast growth factor 7 4.44
NM_014703 Vpr (HIV-1) binding protein 3.92
AI983033 DEAD/H box polypeptide 12 3.91
Cell motility (4.7%) NM_002784 pregnancy specific beta-1-glycoprotein 9 69.22
X99268 twist homolog 1 5.45
NM_015180 spectrin repeat containing, nuclear envelope 2 3.81
AI990816 laminin, alpha 1 3.59
N90777 neuropilin 2 3.57
Cell proliferation (4.5%) NM_016931 NADPH oxidase 4 5.79
AF064826 glypican 4 4.31
NM_004525 low density lipoprotein-related protein 2 3.85
NM_001963 epidermal growth factor (beta-urogastrone) 3.70
AF064103 CDC14 cell division cycle 14 homolog A 3.67
Apoptosis (4.0%) NM_006850 interleukin 24 25.27
NM_002135 nuclear receptor subfamily 4, group A, member 1 5.48
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of that expressed in both KKU-M213 and KKU-M156
CCA cells without transient knockdown of this gene
(Fig 7B). The knockdown effect could be detected up to
72 h after siITGa5 treatment (data not shown). Thus,
the subsequent investigations of cell proliferation and
invasion were done within 72 h after transient knock-
down with siITGa5.
The reduction of ITGa5 expressions in both KKU-
M213 and KKU-M156 CCA cells resulted in a signifi-
cant decreased response of cells to PN-induced cell pro-
liferation and invasion (Fig 7C and 7D). A 104% of
KKU-M213 cell proliferation induction was detected in
siITGa5-treated cells exposed to PN, whereas cell prolif-
eration could increase up to 130% in cells with intrinsic
ITGa5 expression (Fig 7C). In the same manner, KKU-
M156 showed 118% and 98% of cell proliferation induc-
tion observed in cells untreated and treated with
siITGa5.B o t hITGa5-knockdown CCA cell lines did not
respond to PN-activated cell invasion whereas PN dra-
matically induced invasion of both cell lines having nor-
mal intrinsic ITGa5 expression (168% for KKU-M156
and 172% for KKU-M213) (Fig 7D). Finally, cells with
high ITGa5 expressions were more susceptible to PN
stimulation to proliferate and invade than cells without
or minimal ITGa5 expression.
Discussion
Cancer-associated fibroblasts have been recognized for
their impact in the genesis, promotion and progression
of many carcinomas and highlighted in several reviews
[8,25]. CCA is notoriously associated with dense
Table 3: Gene ontology of common down-regulated genes. (Continued)
NM_003823 tumor necrosis factor receptor superfamily 4.59
AJ301610 glutamate receptor, ionotropic, kainate 2 3.92
NM_005809 peroxiredoxin 2 3.90
Only genes in the top-five ranking of each group are shown.
Figure 2 PN expressions in Cfs, CCA cell lines and CCA tissues. PN expression in Cfs measured by real time RT-PCR (A) and western blot
analysis (B) using different biological preparations of Cfs and Lfs from those used in microarray. The expression of PN in CCA cell lines and
fibroblasts extracted from CCA tissues is graphically depicted (C). Results are expressed as mean ± SD of three independent experiments. Means
of PN mRNA expression levels were measured in 20 CCA cases and compared to 5 cases of benign liver diseases using both b-actin and gapdh
as internal controls (D). The positive correlation of mRNA and protein levels of PN in CCA tissues is shown with statistical significance by
Spearman correlation analysis (E).
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Relatively little, however, is known about the contribu-
tion of the stromal fibroblasts to CCA. The authors in
the present group have recently shown that CCA stro-
mal fibroblasts, with and without direct interaction with
cancer cells could induce cancer cell proliferation [6].
Herein, this study focused on the gene expression pro-
file of CCA-derived fibroblasts in order to investigate
the molecular mechanism of how fibroblasts induce a
favorable microenvironment to promote cancer. Even
t h o u g ht h ec u r r e n ts t u d yi sl i m i t e dt oas i n g l ec a n c e r
fibroblast line isolated from a single CCA patient, the
validity of array results was strengthened by comparing
gene expression levels in cancer fibroblasts to the two
lines of normal fibroblasts; one isolated from the same
CCA patient and the other from a second patient. Only
genes in cancer fibroblasts altered from both normal
fibroblast lines were investigated as the common up- or
down-regulated genes. This is to provide evidence that
the fibroblasts used in our study are valid representa-
tives of fibroblasts found in CCA.
By comparing gene profiles in fibroblasts from CCA
with those of other tumor types, it is suggested that
CCA fibroblasts display not only common genotypes for
Figure 3 Immunohistochemical staining of PN in CCA tissues. The expression of PN was localized in fibroblasts but not cancer cells. High
expression of PN was observed in well- (A), moderately- (B) and poorly-differentiated tissues (C), whereas PN negative staining CCA tissue was
demonstrated (D). Benign liver tissue (E) and hepatocellular carcinoma (F) showed no to slight expression. Magnification, 100×. Double
immunofluorescence staining showed co-expression of PN and a-SMA in CCA stromal fibroblasts (G). Magnification, 200×.
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Page 9 of 20activated cells but also unique characteristics. Genes
involved in metabolism of cells needed to be up-regu-
lated in order to support the active function of CCA
stromal fibroblasts to produce many supporting proteins
in the cancer environment. Neuropeptide Y receptor Y1
has been indicated to receive the activation signal to
induce neuroproliferation [26] and doublecortin-like
kinase 1, a microtubule-associated active protein kinase
expressed in growth cones of postmitotic neurons [27]
may help facilitate fibroblast proliferation. In similar to
human basal cell carcinoma fibroblasts [14], SPARC or
osteonectin, was also over-expressed in CCA-derived
fibroblasts. SPARC-null mice were recently demon-
strated to resist UV-induced squamous cell carcinoma,
suggesting a tumor-promoting role of SPARC [28]. In
contrast to the cancer-associated fibroblasts in meta-
static colon cancer to the liver which showed down-reg-
ulation of SDF-1 [18], CCA-derived fibroblasts had up-
regulated SDF-1 (data not shown).
The highly up-regulated genes in CCA-derived fibro-
blasts showed several interesting functions involved in
cancer progression. Serpin peptidase inhibitor, clade B
member 2 (SERPINE2) or plasminogen activator inhibitor
type 2 (PAI2) is involved in cancer invasion and metasta-
sis by controlling serine protease urokinase plasminogen
activator. In a recent review, several studies led to the
suggestion that the significance of PAI2 expression on
prognosis of cancers is organ context-dependent [29]. In
breast cancer, PAI2 was expressed in both stromal and
tumor cells and associated with prolonged disease-free
survival [30]. In contrast, high levels of PAI2 in endome-
trial cancer were reported to correlate with the invasion
potential of the cancer [31]. S100 calcium binding protein
A4 (S100A4) has been revealed as the metastasis-inducing
protein [32]. Genes such as procollagen C-endopeptidase
enhancer 2 (PCPE2) were also detected which may
involve in collagen synthesis [33]. These results support
the function of fibroblasts in CCA to promote a desmo-
plastic reaction. For down-regulated genes, bone morpho-
genetic protein 2 (BMP2A), a multi-functional growth
factor belonging to the transforming growth factor-b
superfamily was decreased in CCA fibroblasts as reported
in breast cancer-derived fibroblasts [13]. BMP2A-encod-
ing protein has been elucidated to induce hypophosphor-
ylation of retinoblastoma protein causing cell cycle arrest
[34]. Hence, decreased BMP2A in the CCA microenvir-
onment may promote cancer cells to enter the cell cycle.
Moreover, a decreased level of interleukin 24 (IL-24), an
apoptotic inducible cytokine [35], in cancer tissues,
attenuates cancer cells from undergoing apoptosis. The
response gene to complement 32 (RGC32), a novel p53-
inducible gene, and bradykinin receptor B1 (BRADYB1)
decreased expression in CCA-derived fibroblasts. Being
intracellular protein and membrane receptor, respectively,
RGC32 and BRADYB1 have elucidated the function of
inhibition of fibroblast cell proliferation [36,37]. It seems
possible to conclude that down-regulated genes in fibro-
blasts encode proteins, if acting in the intracellular
region, can inhibit the proliferation of fibroblasts them-
selves, but if they exist in the extracellular region, they
may involve inhibition of cancer cell proliferation. This
evidence strengthens the roles of fibroblast-derived pro-
Figure 4 Multivariate analysis using Kaplan-Meier method.
Cumulative survival analysis showed significantly shorter survival
time of the patients with high PN expression in fibroblasts when
compared to those who had low PN expression in fibroblasts (P =
0.026).
Table 4 PN expression in CCA tissues compared to benign liver tissues and hepatocellular carcinoma.
Tissues Total cases
(n)
PN expression in fibroblasts
Negative Positive
Low High
CCA 52 9 (17%) 13 (25%) 30 (58%)
Benign liver tissue 8 2 (25%) 6 (75%) 0 (0%)
Hepatocellular carcinoma 4 1 (25%) 3 (75%) 0 (0%)
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Page 10 of 20teins released into a tumor environment to induce a high
proliferative capability of cancer cells.
Fibroblasts have been proposed the bipolar effects in
cancers [38]. In our microarray results, ADAMTS-like 1
(ADAMTSR1) was over-expressed in CCA-derived fibro-
blasts. The ADAMTS-like proteins have been discussed
as the enhancers of ADAMTS proteases [39]. Since
some ADAMTS have been proven to be anti-angiogenic
factors [40] partly via the trapping of vascular
endothelial growth factor by thrombospondin motifs of
ADAMTS [41]. So up-regulation of ADAMTSR1 in
fibroblasts may inhibit angiogenesis. Moreover, stromely-
sin-1 or MMP-3 which can degrade ECM and induce
cancer invasion and metastasis, showed the decreased
expression in fibroblasts. Taken together, the increased
expression of ADAMTSR1 and the decreased expression
of MMP-3 may highlight fibroblasts in term of suppres-
sing CCA progression.
Table 5 Multivariate analysis by Cox proportional hazard regression model for the evaluation of prognostic factors.
Variable
(No. of patients)
No. of dead
patients
Hazard ratio 95% confidence interval P
(5-yr survival cut-off) (HR) (CI)
Age in years
≤ 57 (25) 21 1
>57 (26) 22 1.25 0.62-2.48 0.533
PN expression
Low (22) 17 1
High (29) 26 2.02 1.02-4.02 0.045*
Lymph node metastasis
Absence (36) 28 1
Presence (15) 15 3.13 1.54-6.35 0.002*
Histological type
Well-differentiated (20) 16 1
Moderately-differentiated (8) 8 2.77 1.10-6.98 0.031*
Poorly-differentiated (8) 7 1.64 0.63-4.29 0.310
Papillary (15) 12 0.60 0.25-1.44 0.254
Tumor size (cm)
≤ 5 (28) 23 1
>5 (23) 20 1.49 0.76-2.94 0.251
* P value of equal or less than 0.05 means statistical significance
Table 6 Correlation between PN expression level and clinicopathological parameters.
Variable n PN expression (%) Univariate analysis Multivariate analysis
Low High P HR P
Age in years 0.575
≤ 57 26 10 (38.5) 16 (61.5) 1
>57 26 12 (46.2) 14 (53.8) 0.899 0.870
Sex 0.375
Female 20 10 (50.0) 10 (50.0) 1
Male 32 12 (37.5) 20 (62.5) 1.638 0.452
Histological type 0.083
Well-differentiated 21 8 (38.1) 13 (61.9) 1
Moderately-differentiated 8 1 (12.5) 7 (87.5) 3.720 0.271
Poorly-differentiated 8 6 (75.0) 2 (25.0) 0.184 0.86
Papillary 15 7 (46.7) 8 (53.3) 0.611 0.505
Tumor size (cm) 0.123
≤ 5 29 15 (51.7) 14 (48.3) 1
>5 23 7 (30.4) 16 (69.6) 2.493 0.161
Lymph node metastasis 0.830
Absence 37 16 (43.2) 21 (56.8) 1
Presence 15 6 (40.0) 9 (60.0) 1.459 0.590
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Page 11 of 20Figure 5 PN promotes cell proliferation of CCA cell lines. KKU-M156, KKU-M213 and KKU-M055 showed significantly induced proliferation
with different concentrations of PN (A-C) whereas KKU-100 was unresponsive to PN (D). With an optimal dose of PN for each cell line, KKU-
M213, KKU-M156, and KKU-M055 increased cell proliferation in a time-dependent manner (E). Triplicate experiments were performed for each
assay. Results are expressed as mean ± SD and an asterix represents a P value less than 0.05 when compared to the negative controls without
PN treatment. Black and dashed lines represent cells with and without PN treatment, respectively. Colony formation assay with and without agar
was performed (F). Colony of more than 30 cells was counted under inverted microscope. Numbers of colonies/well in 6-well plate of both KKU-
M213 and KKU-M156 CCA cell lines were higher in condition of PN treatment than those without PN. Results are expressed as mean ± SD of
duplicate experiments. Pictures of crystal violet-stained cells are of KKU-M213 CCA cells in comparison between with and without PN.
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Page 12 of 20Figure 6 Cell cycle distribution and invasion analysis of cancer cells with and without stimulation by PN. Cell cycle analysis of KKU-M213
and KKU-M156 induced by PN (A). PN could drive cells from G1 into S and G2/M phases of the cell cycle when compared to control cells
without PN treatment (B). Invasion induction by PN on KKU-M213 and KKU-M156 CCA cell lines is shown (C). Numbers of invaded cells when no
PN was used served as control and were adjusted to be 100% (white bar). The increase of invaded cells induced by PN is observed and shown
by a black bar. Each bar graph represents mean ± SD of three independent experiments. An asterix represents a P value of less than 0.05.
Utispan et al. Molecular Cancer 2010, 9:13
http://www.molecular-cancer.com/content/9/1/13
Page 13 of 20Theoretically, proteins secreted from fibroblasts having
interplay with cancer cells could be detected in the
extracellular region and be involved in ECM organiza-
tion and biosynthesis. Within these 2 groups of genes,
we focused our interest on genes encoded secreted pro-
teins and their products have been previously reported
of their tumorigenic effects. ADAM12, AREG, AGN2,
ER, JAGL1, LAMA5, NOV, PDGF-A, PN, RL,a n dSCG2
were selected to explore. AREG, ER, JAGL1,a n d
LAMA5 are predominantly reported for proliferation
induction in cancer cells [42-45]. PDGF-A, NOV, AGN2,
and SCG2 are involved in angiogenesis [46-49], whereas
ADAM12 and RL play an important role in cell motility,
invasion and metastasis [50,51]. For PN, many carcino-
genic functions including cell proliferation, invasion,
metastasis and angiogenesis have been demonstrated
[20-24]. This study employed real time PCR to verify
the up-regulation of these genes, and found that only
ADAM12, AREG, ER, JAGL1, PDGF-A, PN and SCG2
were significantly increased in their expression levels in
CCA-derived fibroblasts and may promote CCA pro-
gression through activation of cancer growth, invasion
and angiogenesis.
Herein PN was chosen to deeply explore since its well
accepted multifunction in cancer as mentioned above.
Moreover, the result from our group about the expres-
sions of ADAM12, AREG, ER, JAGL1, PDGF-A, PN and
SCG2 in whole CCA tissues (n = 20) showed that only
AREG, PDGF-A and PN had higher level in cancer than
those in benign liver tissues with statistical significance
(data not shown). AREG and PDGF-A could be detected
in not only fibroblasts but also in cancer and endothelial
Figure 7 Effect of siITGa5 on PN-induced proliferation and invasion of CCA cells. Lipofectamine-treated cells (mock) had nearly the same
viability as siITGa5-treated cells (A). KKU-M213 and KKU-M156 showed dramatically decreased expression of ITGa5 detected by real time RT-PCR
after exposure to siITGa5 (B). Percentage of proliferation and invasion compared to control mock cells is shown. The siITGa5-treated cells
(negative ITGa5) could not respond to PN in induction of proliferation as much as that detected in cells without exposure to siITGa5 (positive
ITGa5) (C). A similar effect was observed in PN-induced invasion of CCA cell lines (D). Results represent mean ± SD of three independent
experiments and an asterix represents significantly increased cell proliferation and invasion by PN compared to mock cells without PN treatment.
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blasts. In order to demonstrate role of fibroblast-derived
proteins in CCA, we determined that PN should be the
first target to explore.
The strong evidence using different biological prepara-
tions of CCA-derived fibroblasts and CCA tissues con-
firmed the increased levels of PN at both mRNA and
protein. Most of CCA tissues of all differentiated types
had high levels of PN and expressed exclusively in a-
SMA positive fibroblasts. In the same direction, the find-
ings showed no expression of PN in CCA cell lines when
compared to the high level expressed in the fibroblasts.
This may strengthen the results of the absence of PN in
cancer cells in CCA tissues. From these results taken
together, it can be concluded that PN detected in CCA
tissues is only of fibroblast origin as reported in some
cancers [52-54]. In cancers of head and neck, ovary, and
colon, PN was found in cancer cells and has been pro-
posed to induce tumorigenic properties of cancer cells
via an autocrine mechanism [21,22]. Hence results from
the present study allow the speculation to propose a phe-
nomenon that fibroblast-derived PN in CCA may affect
cancer cells by a paracrine mode and has a promising
role in cancer promotion. These results revealed that a
high PN level in fibroblasts was an independent risk fac-
tor in CCA patients and those having high PN had signif-
icantly low cumulative survival time after surgery. PN
might therefore be used as a poor prognostic marker in
patients suffering from CCA. Detections of PN at both
mRNA and encoding protein in CCA tissues are in the
same direction to distinguish CCA from non-cancer syn-
dromes of bile ducts. In addition, most benign liver tis-
sues and hepatocellular carcinoma showed no to only a
minimal expression of PN when compared to the high
level detected in CCA tissues. Hence, serum PN may
help to distinguish CCA from benign conditions and clo-
sely-related liver cancer and may use as the prognostic or
predictive marker as previously reported [52,55].
To show the tumorigenic impacts of PN on CCA cells,
recombinant PN was employed as extracellular PN to
mimic the paracrine effect of PN produced from cancer
stromal fibroblasts to induce CCA cell proliferation and
invasion. Though receptors ITGavb3 and ITGavb5 have
been shown to be the receptors for PN in several cancer
cells [21], PN promoted invasiveness of pancreatic can-
cer cells via the b4 integrin [56]. This suggests the cell
type dependent on a specific ITG responded to PN. The
study herein reveals that PN-induced cell proliferation
and invasion could be inhibited by RNAi against ITGa5.
Hence, ITGa5 is a potentially promising receptor for PN
in CCA cells. As the well known receptor for fibronec-
tin, the apparent reason for ITGa5 production in CCA
cells is to support the abundance of fibronectin found in
CCA [57]. In addition, ITGa5 c a no n l yb ef r o m
dimerization with the b1 subunit and activation of
ITGa5b1 has been revealed to support cell survival [58]
and induce invasion and angiogenesis [59,60]. Though
further studies need to be performed before such a con-
clusion is valid in CCA, this work highlights the PN-
induced-ITGa5 pathway as one of the activated path-
ways to induce an aggressive CCA.
TGF-b has been proposed to induce the expression of
PN [61]. O. viverrini excretory/secretory product has
also recently been shown to be the stimulator of fibro-
blast proliferation via the TGF-b-mediated signal trans-
duction pathway [62] and this pathway seems likely to
be the cause of PN expression in CCA-derived fibro-
blasts. The authors’ laboratory has checked the effect of
parasitic product-treated fibroblasts and found that
these fibroblasts increased PN expression compared to
the normal liver fibroblasts without exposure (unpub-
lished data). It is interesting to propose that in CCA
cells; the expression of fibroblast-derived PN could be
induced by TGF-b produced from infected parasites
since the early stage of carcinogenesis and may be in
concert with TGF-b produced from CCA cells in a late
stage of cancer [12]. Though in vivo experiments are
needed to confirm, fibroblast-derived PN may influence
O. viverrini-associated CCA at the early stage of cancer
as well as to promote cancer progression in the later
time. With this information, targeting the stroma in
CCA may not only be effective in treatment of primary,
invasive and metastatic tumors, but may also play role
in prevention of tumor development.
Conclusions
To the authors’ knowledge, this study is the first to
describe the gene expression profile of CCA-derived fibro-
blasts. Molecular understanding of fibroblasts in CCA by
the functions of certain up- and down-regulated genes has
been revealed and has suggested certain groups of genes in
controlling cancer cell proliferation, invasion, metastasis
and angiogenesis (Fig 8). These findings provide evidence
that fibroblasts are important sources of tumorigenic sub-
stances, particularly PN, when produced into the microen-
vironment of CCA. High levels of PN are found in most
CCA patients and can be used as a poor prognostic mar-
ker. In addition, the level of PN can be used to distinguish
CCA from other benign liver conditions and hepatocellular
carcinoma. The interaction of fibroblast-derived PN and
CCA cells helps to promote cell proliferation and invasion
probably via ITGa5. Though further investigations are
needed, this study suggests promising evidence of the value
of using serum PN as a prognostic marker of poor survival
in CCA patients. Moreover, targeting fibroblasts or fibro-
blast-derived-PN-stimulated pathways in cancer cells to
attenuate the tumorigenic induction of PN is a further
challenge to inhibit CCA progression in the patients.
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Cells and culture condition
Cfs and Lfs were established and characterized in this
lab as previously reported [6]. CCA cell lines including
KKU-M213; KKU-M156; KKU-M055; and KKU-100
were received as a kind gift from Associate Professor
Dr. Banchob Sripa (Khon Kaen University). Cfs and Lfs
were grown in the complete media which is 10% FBS
containing DMEM with 20% epidermal growth factor
(CytoLab Ltd., Rehovot, Israel). CCA cells were cultured
in 10% FBS containing Ham-F12 (Invitrogen, Carlsbad,
CA) supplemented with antibiotics and an anti-fungal
agent at 37°C and in 5% CO2 incubator.
Gene expression profiling study and data analysis
Total RNA was extracted using RNeasy Micro Kit (Qia-
gen, Valencia, CA) using the manufacturer’s instructions.
The quality of the RNA was assessed by an Agilent RNA
6000 Nano Kit (Agilent Technologies, Waldbronn, Ger-
many). Affymetrix GeneChip Human Genome U133 plus
2.0 Array containing 38,500 human genes (Affymetrix,
Santa Clara, CA) was used following Affymetrix’s instruc-
tion. The array data were scanned by a GeneChip Scanner
3000 (Affymetrix) and analysed by Affymetrix microarray
suite, version 5.0. Raw data from the GeneChips were
used to analyze expression levels and expressed as fold
changes and gene ontology was categorized by Gene
Spring G.X.7.3 software (Agilent Technologies). Average
fold change of gene expression was determined by inten-
sity comparison between Cf and Lf1 and Lf2.
Semi-quantitative real time PCR
Complementary DNA was synthesized from 1 μgo f
total RNA using the first strand cDNA synthesis kit
(AMV) (Roche Molecular Biochemicals, Mannheim,
Germany) according to the instructions. Relative expres-
sion levels in genes of Cfs and Lfs were determined by
SYBR Green-based real time PCR using ABI 7500
(Applied Biosystem, Foster City, CA) and calculated by
the 2
-ΔΔC
T equation. In this case, ΔCT =C T (Cf)-CT
(Lf). b-actin served as an internal control to adjust the
amount of starting cDNA. The sequences of genes
tested in this study were retrieved from PubMed http://
www.ncbi.nlm.nih.gov and the primers were designed by
Primer 3 (Table 7).
Human CCA tissues and immunohistochemistry
Fifty-two cases of CCA tissues were obtained from
patients who had undergone hepatectomy using the pro-
tocol approved by the Human Research Ethics Commit-
tee, Khon Kaen University (HE490143). The age, sex,
tumor size, histological type and staging data were
derived from the medical charts and pathological
records. Benign liver tissues were characterized as
chronic inflammation by other causes rather than CCA.
Paraffin-embedded tissues were used and antigens
were retrieved in 10 mM citrate buffer pH 6.0 at 95°C
for 40 min and endogenous peroxidase was blocked in
3% H2O2 for 5 min. After blocking non-specific binding
with 2% bovine serum albumin for 20 min, 1:10,000 rab-
bit anti-human PN (Biovendor, Heidelberg, Germany)
Figure 8 Proposed impacts of CCA-associated fibroblasts revealed in this study. A schematic representation of the main alterations in
CCA-associated fibroblasts revealed in this study. The biological functions of protein products from the up-regulated genes in fibroblasts are
represented. Tumorigenic effects of PN on CCA cancer cells are also proposed.
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night, followed by anti-rabbit Envision
+ System-HRP
labeled polymer (Dako, Carpinteria, CA) for 30 min at
room temperature. The immunoreactive signal was
developed by diaminobenzidine (DAB; Sigma, St Louis,
MO) and counterstained with hematoxylin. The signal
was checked under light microscope.
PN expression of intratumoral fibroblasts on the histo-
logic sections was semi-quantitatively scored on the basis
of PN-positive fibroblasts percentage and the immunos-
taining intensity. The number of positive fibroblast cells
were classified as < 10% (negative); 10-25% (+1); 26-50%
(+2); and >50% (+3). The intensity of PN expression in
fibroblasts was scored no staining, 0; weak staining, 1;
intermediate or focal weak and focal intense staining, 2;
intense staining, 3. The interpretation of PN expression
was performed by summarization the scores of the per-
cent positive cell (0-3) and the scores of staining intensity
(1-3) to reach the total final score of 0-6. The results
were then categorized as follows; low expression, score ≤
4; and high expression, score > 4. All samples were anon-
ymized and independently scored by one pathologist
(KC) and 2 investigators (PT and CT). In case of dis-
agreement, the slides were reexamined and a consensus
was reached by at least 2 observers.
Double immunofluorescence staining of a-SMA and PN
In order to localize the expression of PN and a-SMA in
CCA tissues, double immunofluorescence staining was
performed. The 1:200 mouse anti-human a-SMA antibody
(Sigma) and 1:500 rabbit anti-human PN antibody (Bio-
vendor) were used as primary antibodies. Anti-mouse
IgG-Alexa 488 and anti-rabbit IgG-Cy3 (Invitrogen) were
used as the second antibodies. Nucleus was stained with
Hoechst (Invitrogen). The signal was observed under the
LSM 510 Meta laser scanning confocal microscope (Carl
Zeiss, Jena, Germany) at the Division of Medical Molecu-
lar Biology, Office for Research and Development, Faculty
of Medicine Siriraj Hospital, Mahidol University.
Protein extraction and western blot analysis
Twenty μgs of total protein from the cell lysate were sepa-
rated in 10% SDS-PAGE and transferred onto a PVDF
membrane (Millipore, Billerica, MA). For PN detection,
1:500 rabbit anti-human PN (Biovendor) and 1:1,000 goat
anti-rabbit conjugated HRP (Abcam, Cambridge, MA)
were used. The signal was visualized by ECL (Pierce, Rock-
ford, IL). The expression of b-actin was used as an internal
control to determine an equal amount of loading proteins.
Cell proliferation assay
CCA cells with or without treatment with siITGa5 cells
were arrested in HAM-F12 without serum supplement
for 12 h. Different concentrations of recombinant PN
(Biovendor) prepared in 1% FBS containing HAM-F12
were incubated with cells for 6, 12 and 24 h. The viable
cells in each condition were determined using an MTS
assay (Promega, Madison, WI) according to the manu-
facturer’s instruction.
Cell cycle analysis by flow cytometry
Cell cycle distribution analysis used cells stained with
propidium iodide (Invitrogen) as previously described
[63]. The distribution of cells in each stage of the cell
cycle was quantitated in a flow cytometer and CellQuest
software (Becton Dickinson, Franklin Lakes, NJ).
Table 7 Primer sequences for real time PCR.
Gene Forward Primer Reverse Primer Size Accession no.
5’-3’ 5’-3’ (bp)
ADAM12 tttgggggtcaacagttttc agagctgggttcccttttgt 191 NM_003474
AREG tggggaaaagtccatgaaaa tttcgttcctcagcttctcc 174 NM_001657
AGN2 ccacctgaggaactgtctcg ggtcttgctttggtccgtta 191 NM_001147
ER catatgggagaagggggagt aagtgcaattacagagtgcaaaa 166 NM_001432
JAGL1 gcctgccttaagtgaggaaa gccaagaacaacacatcaaaga 169 U77914
LAMA5 gtgatgaaaagcgggaatgt acctccacagagcgagtcat 221 BC003355
NOV tgcaattccaagaaaatatcactg cttggatttggagcttggaa 167 NM_002514
PDGF-A acacgagcagtgtcaagtgc tctggttggctgctttaggt 250 X03795
PN cactctttgctcccaccaat tcaaagactgctcctcccata 157 AY140646
RL tgctgaatttggggctactt gggagatagggtcttcatcca 198 NM_005045
SCG2 cccgaagaatgatgataccc aaatgttgggatttgcttgg 195 NM_003469
ITGa5 agttgcatttccgagtctgg ccaaacaggatggctaggat 223 NM_002205
b-actin cacactgtgcccatctacga ctccttaatgtcacgcacga 162 X00351
gapdh ctcctcctgttcgacagtca gttaaaagcagccctggtga 140 NM_002046
Note: ADAM12, a disintegrin and matrix metalloproteinase 12; AREG, amphiregulin; AGN2, angiopoietin 2; ER, epiregulin; JAGL1, jagged soluble form; LAMA5,
laminin alpha 5; NOV, nephroblastoma over expressed; PDGF-A, platelet-derived growth factor alpha; PN, periostin; RL, reelin; SCG2, secretogranin 2; ITGa5,
integrin alpha 5; b-actin, beta-actin; gapdh, glyceraldehyde 3-phosphate dehydrogenase
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cell cycle were measured and compared between condi-
tions with and without recombinant PN treatment.
These experiments were repeated two times using repli-
cate culture dishes in the same experiment.
Colony formation assay
CCA cell lines were cultured in 6-well plate. After 24-h
culture, recombinant PN diluted in 1% FBS containing
medium was added and the plate was incubated in CO2
incubator. Soft agar colony formation assay was also
performed using 0.5% and 0.35% MetaPhor® agarose
(Cambrex Bio Science, Rockland, ME) as lower and
upper layers, respectively. After 12 d, cells were fixed
with 5% v/v glutaraldehyde and stained with 0.5% w/v
crystal violet in 40% v/v methanol. Cell growth was esti-
mated by counting numbers of colonies with more than
30 cells under inverted microscope and compared
between those of treat and untreated with PN. The
experiment was performed in duplicate.
Invasion assay
KKU-M213 and KKU-M156 CCA cells were seeded in
PN (100 ng/ml) containing medium into the Matrigel
invasion chamber (BD Biosciences, San Jose, CA) and
incubated for 24 h. Invaded cells were fixed with 5% v/v
glutaraldehyde and stained with 0.5% w/v crystal violet
in 40% v/v methanol for 30 min each. The number of
invaded cells was counted under a microscope by two
independent investigators using 100× magnification
fields. The assays were done in replicate and three inde-
pendent experiments were performed.
Small interfering RNA against receptor integrin a5
Two hundred thousand CCA cells were seeded into a 6-
well plate for 24 h before transfection of siITGa5 (Santa
Cruz Biotechnology, Santa Cruz, CA) by Lipofectamine
2000 (Invitrogen). Three siRNA strands (5’-guca-
gaauuucgagacaaa-3’,5 ’-caccaacaagagagccaaa-3’,a n d5 ’-
ccacugaccagaacuagaa-3’)w e r eu s e dt ot a r g e tITGa5
mRNA. The efficiency of knock down was tested by real
time PCR using b-actin as an internal control.
Statistical analysis
Statistical analyses were performed using SPSS version
16.0 (SPSS Inc., Chicago, IL). The correlation of PN
expression and pathological parameters of CCA
patients was analyzed by the c
2-test and binary logistic
multivariate analysis. Patient survival was calculated
from the time of surgical resection to death and the
survival curves were constructed according to Kaplan-
Meier, with a Log-Rank test. A multivariate analysis
was performed by the Cox proportional hazard regres-
sion model. The significance of the different data was
determined by the Student’st - t e s t .AP value of equal
to or less than 0.05 was defined as statistically
significant.
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